Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monitoring consistently to assess clinical outcomes in response to therapy allows for quick therapeutic adjustments before bowel damage can occur. Point-of-care intestinal ultrasound performed by the treating gastroenterologist is an accurate cross-

sectional biomarker that monitors intestinal inflammation in real-time, enhances patient care, and increases shared understanding to help achieve common treatment goals. Combining intestinal ultrasound during a clinic visit with existing serum and stool biomarkers in a home testing setup with electronic health monitoring allows for an optimized, patient-centered personalized treatment algorithm that may improve treatment outcomes. Here, we review the current state, pragmatic considerations, and future implications of point-of-care testing and home testing for noninvasive inflammatory bowel disease monitoring in the tight control model.

突破炎症性肠病的生物治疗疗效平台，需要在严格控制模型中战略性地开发个性化的生物标志物。在疾病病程早期进行风险分层后，持续进行有针对性的连续监测以评估治疗反应的临床结果，从而在肠道损伤发生之前快速调整治疗。由治疗胃肠病学家进行的即时肠道超声检查是一种准确的交叉检查。

实时监测肠道炎症、增强患者护理并增加共同理解以帮助实现共同治疗目标的截面生物标志物。将门诊就诊期间的肠道超声与家庭测试设置中现有的血清和粪便生物标志物与电子健康监测相结合，可以实现优化的、以患者为中心的个性化治疗算法，从而改善治疗结果。在这里，我们回顾了在严格控制模型中无创炎症性肠病监测的即时检测和家庭检测的现状、务实考虑和未来影响。